The asthma-COPD overlap syndrome: a new entity?

Miriam Barrecheguren, Cristina Esquinas and Marc Miravitlles*

Summary
Asthma and COPD are the most frequent chronic respiratory diseases. Although they have different characteristics, some individuals share features of both diseases, which has been called the asthma-COPD overlap syndrome (ACOS). Although there is not a universally accepted definition for ACOS, it was initially defined as symptoms of increased variability of airflow in association with an incompletely reversible airflow obstruction. The most recent COPD guidelines include this phenotype and its diagnostic features. Patients with ACOS are usually characterized by increased reversibility of airflow obstruction, eosinophilic bronchial and systemic inflammation, and increased response to inhaled corticosteroids, compared with COPD patients. The relevance of the ACOS is the need to identify patients with COPD who may have underlying eosinophilic inflammation that responds better to inhaled corticosteroids. Until new diagnostic tools are developed, a previous diagnosis of asthma in a patient with COPD can be a reliable criterion to suspect ACOS in a patient with COPD but a comprehensive approach may be required in most cases for a definitive diagnosis of ACOS.

Keywords: COPD, Asthma, ACOS, Phenotypes, Treatment

Introduction
Chronic obstructive pulmonary disease (COPD) is an underdiagnosed disease with a high morbidity and mortality and is a very significant public health problem. In Europe the estimated prevalence varies from 2.1 % and 26.1 % between countries [1]. Given its high prevalence, COPD entails a high burden in all the levels of care.

In recent years, there has been a growing interest in defining and characterising COPD patients into different phenotypes that share clinical features, similar response to the available treatments and that may have prognostic implications [2, 3]. Among these, the asthma-COPD overlap syndrome (ACOS) is a clear example that fulfils all the criteria and is currently kindling great interest.

COPD and asthma have clear differences, but some patients may present with a mixture of both diseases. ACOS may be a manifestation of characteristics of the asthma and COPD that the patient is suffering from. Clinically, the ACOS usually corresponds to asthmatic smokers who develop non-fully reversible airway obstruction, however, when the previous history of asthma is unknown, the diagnosis of ACOS may be difficult due to the lack of specific biomarkers. In many cases the correct diagnosis of ACOS will require a comprehensive approach including clinical manifestations, spirometry with bronchodilator test, identification of eosinophilic inflammation, lung volumes and carbon monoxide diffusion capacity and even CT scan, and such diagnosis should be made by a specialist [4].

The interest in recognizing these individuals lies in their better response to inhaled corticosteroids (ICS) compared to those with COPD. This specific and differential treatment justifies the efforts to differentiate the subgroup of patients with ACOS from the large population of COPD patients.

Definition and clinical features
From a COPD perspective, the identification of ACOS is relevant to describe a subgroup of smokers with COPD that share some pathogenic and inflammatory characteristics with asthma. Patients with ACOS are also more likely to be frequent exacerbators (defined as the presence of 2 or more exacerbations per year), to have reduced physical activity, worse quality of life and more...
respiratory symptoms, particularly dyspnoea and wheezing, than patients with COPD alone [5, 6].

ACOS has been defined as symptoms of increased variability of airflow in association with incompletely reversible airflow obstruction [7]. More recently, Louie et al. [8] defined ACOS as asthma with partially reversible airflow obstruction, with or without emphysema or reduced carbon monoxide diffusing capacity (DLCO) to <80 % predicted, and COPD with emphysema accompanied by reversible or partially reversible airflow obstruction, with or without environmental allergies or reduced DLCO. Izquierdo-Alonso et al. [9] identified ACOS as patients with COPD (more than 10 pack-years of smoking and post-bronchodilator FEV1/FVC < 0.7) and a personal history of asthma before the age of 40, with the addition of normal carbon monoxide (CO) diffusing capacity and the absence of pulmonary emphysema demonstrated by imaging techniques.

It is important to recognise that the presence of chronic non-fully reversible airflow obstruction in a subject with asthma is not necessarily ACOS. It is well known that severe asthma patients may develop non-reversible airflow limitation without any characteristics of COPD [10]. The definition of ACOS is also included in some of the latest guidelines. The Spanish guidelines of COPD identify ACOS patients based on some diagnostic criteria: A) Major criteria: very positive bronchodilator response (>400 ml and >15 % in FEV1), sputum eosinophilia or previous diagnosis of asthma. B) Minor criteria: increased total serum IgE, previous history of atopy or positive bronchodilator test (>200 mL and >12 % in FEV1) on at least two occasions [11, 12]. To be diagnosed with ACOS, a patient must fulfil two major or one major and two minor criteria. The recent Czech Republic and Finnish guidelines also include ACOS with its own diagnostic criteria. In the Czech Republic diagnostic guidelines major criteria include a strong bronchodilator test positivity (FEV1 > 15 % and >400 ml), positive bronchial challenge test, FeNO > 45–50 ppb and/or sputum eosinophilia ≥3 % and a previous history of asthma, and as minor criteria: mild bronchodilator test positivity (FEV1 > 12 % and >200 ml), increased total IgE and history of atopy [13]. The main Finnish diagnostic criteria are also a significant bronchodilatory effect (FEV1 > 15 % and >400 ml), sputum eosinophilia or elevated ENO (>50 ppb) and previous asthma symptoms (starting before the age of 40). As additional criteria they include an elevated total IgE, atopy, repeated significant bronchodilatory response (FEV1 > 12 % and >200 ml) and a PEF-follow up typical of asthma [14]. For both guidelines, a patient must fulfil two major (or main) criteria or one major and two minor (or additional) criteria.

A recent GOLD-GINA document about ACOS describes this syndrome as persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD [15].

**Diagnosis: current and future strategies**

In asthma the term endotype has been introduced to identify subtypes of patients defined by a distinct functional of pathophysiological mechanism [16]. It is possible that different mechanisms in patients suffering from asthma or COPD could lead to the clinical expression that we now define as ACOS. Most studies define ACOS as a phenotype of COPD. There is no unified definition of ACOS but some main features can help us to identify this phenotype. In patients with COPD, increased reversibility is one of the key differential aspects of individuals with ACOS, but it can be misleading if taken alone. Significant reversibility in COPD is common and observed frequently in clinical practice and in series of patients included in clinical trials [17]. Somewhat more than 50 % of the patients with moderate-to-very-severe COPD in the UPLIFT clinical trial met the most commonly used criteria for acute bronchodilator responsiveness [18]. Related to this bronchodilator response, bronchial hyperresponsiveness (BHR) is observed in almost all patients with asthma, especially in those with active symptoms and in up to two-thirds of COPD patients [19]. Furthermore, BHR is observed in approximately 10 % to 20 % of the general population and has shown to be a risk factor of developing asthma and COPD [8]. In patients with established asthma or COPD, more severe BHR is associated with more severe symptoms and a more rapid decline in FEV1 [20]. Nevertheless, in a population of COPD patients without significant comorbidities, individuals with high levels of reversibility presented better long-term outcomes [21]. These controversial results underscore the need of a specialised approach to the diagnosis and assessment of the patients with ACOS.

Possibly the most important diagnostic feature of ACOS in COPD is the presence of sputum eosinophilia. Inflammation in asthma patients is considered to be mainly eosinophilic and mediated by CD4+ T lymphocytes while in COPD it is neutrophilic and driven by CD8+. Papi et al. [22] observed that peripheral eosinophilic counts and sputum eosinophil counts were significantly higher in stable COPD patients with partial reversibility of airflow limitation compared to COPD patients without reversibility. Since sputum eosinophilia is not routinely performed in clinical practice, indirect markers of this type of inflammation have been investigated. Chou et al. [23] demonstrated higher levels of exhaled nitric oxide (eNO) in patients with COPD and eosinophilic airway inflammation (>3 % eosinophils in induced sputum), with a cut off of 23.5 ppb of eNO having a sensitivity of 62.1 % and a specificity of 70.5 % for the identification of eosinophilic
inflammation. Interestingly, patients with COPD and peripheral eosinophilic inflammation treated with ICS present fewer exacerbations compared to those with lower blood count levels [24].

Other plasma and sputum biomarkers of ACOS are currently being studied. Iwamoto et al. [25] investigated four potential biomarkers in COPD (surfactant protein A (SP-A), soluble receptor for advanced glycation end products (sRAGE), myeloperoxidases (MPO) and neutrophil gelatinase associated lipocalin (NGAL)). Compared with asthma patients, sputum MPO and plasma SP-A were significantly elevated in ACOS, while only sputum NGAL was significantly increased compared to COPD. Fu et al. [26] examined the levels of the systemic inflammation markers PCR and IL-6 in asthma, COPD and ACOS patients and identified potential clinical characteristics that were associated with these biomarkers. They found a high prevalence of systemic inflammation in older people with ACOS and an elevated IL-6 compared with asthma patients. Age, Charlson comorbidity index and IL-6 were independently associated with ACOS while IL-6 was independently associated with airflow obstruction and cardiovascular disease suggesting that it may be involved in these two processes and may therefore be an independent treatment target [26].

There is a growing interest in the identification of genetic determinants for ACOS. Genetic analysis of the COPD gene cohort identified several variants associated with ACOS, which may demonstrate distinct genetic risk factors [27]. Christenson et al. [28] investigated whether asthma-associated gene signatures were increased in a subgroup of COPD patients and associated with asthma-related features, consisting in eosinophilia and type 2 (TH2) inflammation. In their study, the investigators developed a 100 gene signature of the Th2-related gene expression, the T2S score that correlated well with Th2-associated clinical characteristics in asthmatic patients and found that approximately 20 % of their COPD patients had increased expression of T2S. They next investigated the association of T2S with clinical parameters in the GLUCOLD cohort of patients with COPD. T2S was significantly associated with increased tissue eosinophil numbers, increased serum eosinophil percentage and increased bronchodilator responsiveness (Fig. 1). Interestingly, a higher T2S was associated with greater reduction in hyperinflation after ICS (with or without LABA) treatment versus placebo at 30 months [28]. Nevertheless, albeit promising, these techniques are not available in every centre and cannot yet be used as a diagnostic tool in clinical practice.

Epidemiology of ACOS

Data derived from large population studies have revealed that a high proportion of adult patients with respiratory symptoms are commonly diagnosed with more than one obstructive lung disease, especially elderly individuals [29].

More interesting is the prevalence of ACOS observed among populations of patients diagnosed with COPD. This prevalence can be estimated from research databases or clinical studies. The prevalence of ACOS derived from clinical studies is usually lower compared with the analysis of databases, due to the use of more restrictive diagnostic criteria. Using the criteria established by the Spanish National Consensus Conference (Table 1), in a cross sectional study with 279 COPD patients Miraвитles et al. [30] observed a prevalence of ACOS of 5 %. A larger survey in 3125 COPD patients using the same

![Fig 1](image_url) Clinical expression of the asthma-COPD overlap syndrome (ACOS). The ACOS usually corresponds to a smoker asthmatic patient that develops non fully reversible airway obstruction and/or a COPD individual (with or without a known history of asthma) with a Th2 signature (increased blood and lung eosinophilia, increased airway hyper-responsiveness, and better response to ICS). Reproduced with permission from ref. [43]
criteria observed a prevalence of ACOS of 3.9 %. However, this prevalence increased to 15.9 % when using the criterion of a previous diagnosis of asthma [31]. In a retrospective observational study of 499 patients with COPD Golpe et al. [32] observed a similar prevalence (5 %) in smoking-related COPD patients but with a higher frequency of ACOS in COPD patients caused by inhalation of biomass smoke (21.2 %). Following modified criteria from the Spanish consensus that included a normal diffusion capacity for carbon monoxide (DLCO), Izquierdo-Alonso et al. [9] detected a prevalence of ACOS of 12 % in an observational, multicentre study.

### Table 1 Asthma-COPD overlap syndrome, definitions and diagnostic criteria

<table>
<thead>
<tr>
<th>Source</th>
<th>Definition and Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gibson P, Simpson J [7], 2009</td>
<td>Asthma and COPD (symptoms of increased variability of airflow and incompletely reversible airflow obstruction)</td>
</tr>
<tr>
<td>COPD gene [5], 2011</td>
<td>Patients with COPD and a diagnosis of asthma before the age of 40</td>
</tr>
</tbody>
</table>
| Spanish consensus [11], 2012 (patients must fulfill 2 major criteria or 1 major and 2 minor) | **Major criteria**  
- Very positive bronchodilator response (>400 ml and >15 % in FEV1)  
- Sputum eosinophilia  
- Previous diagnosis of asthma  
**Minor criteria**  
- Increased total serum IgE  
- Previous history of atopy  
- Positive bronchodilator test (>200 mL and >12 % in FEV1) on at least two occasions |
| Czech Republic guidelines [13], 2013 (patients must fulfill 2 major criteria or 1 major and 2 minor) | **Major criteria**  
- Strong bronchodilator test positivity (FEV1 > 15 % and > 400 ml)  
- Positive bronchial challenge test  
- FeNO > 45–50 ppb and/or sputum eosinophilia ≥ 3 %  
- History of asthma  
**Minor criteria**  
- Mild bronchodilator test positivity (FEV1 > 12 % and > 200 ml)  
- Increased total IgE  
- History of atopy |
| Louie S et al. [8], 2013 | - Asthma with partially reversible airflow obstruction with/without emphysema or reduction of DLCO <80 % predicted.  
- COPD with emphysema accompanied by reversible or partially reversible airflow obstruction, with or without environmental allergies or reduced DLCO |
| Menezes M et al. [30], 2013 | FEV1/FVC <0.7 and medical diagnosis of asthma or wheezing + positive bronchodilator test (>200 mL and >12 % in FEV1) |
| Izquierdo-Alonso et al. [9] (2013) | COPD (more than 10 pack-years and post bronchodilator FEV1/FVC < 0.7)  
- History of asthma before the age of 40  
- Normal carbon monoxide (CO) diffusion capacity and absence of pulmonary emphysema demonstrated by imaging techniques |
| GOLD-GINA document [15] (2014) | Persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD |
| Finish guidelines [14] (2014) (patients must fulfill 2 main criteria or 1 main and 2 additional) | **Main criteria**  
- Significant bronchodilatory effect (FEV1 > 15 % and > 400 ml)  
- Sputum eosinophilia or elevated ENO (>50 ppb)  
- Previous asthma symptoms (starting before the age of 40)  
**Additional criteria**  
- Elevated total IgE  
- Atopy  
- Repeated significant bronchodilatory response (FEV1 > 12 % and >200 ml)  
- PEF-follow up typical of asthma |
performed in 331 COPD patients recruited in pulmonology outpatient services. Similar frequencies have been described in studies performed in other countries [5, 8]. In the COPD Gene study, Hardin and colleges found that 13 % of subjects with COPD also reported physician-diagnosed asthma [5]. In epidemiological studies such as the PLATINO study performed in Latin America, a prevalence of 11.6 % was described using a postbronchodilator FEV1/FVC < 0.7 and asthma diagnosis as ACOS criteria [33]. In the Spanish EPISCAN epidemiological study, including patients with COPD and previous diagnosis of asthma before the age of 40, a prevalence of 17.4 % of ACOS was observed among the COPD population [34].

Treatment
There is little information about the response of ACOS patients to most of the current pharmacological therapies as they have been systematically excluded from both COPD and asthma pharmacological trials. The only clinical trial performed to date in patients with ACOS studied the effects of tiotropium in 472 individuals with concomitant COPD and asthma. Improvements in lung function and a reduction in rescue medication were observed with tiotropium [35]. However, the main interest in differentiating ACOS from COPD lies in the different response to ICS. Some studies demonstrate that patients with COPD and eosinophilic inflammation treated with ICS present a significant improvement in bronchial inflammation together with clinical and spirometric improvement [36, 37]. Two small, randomised trials have demonstrated that prescribing corticosteroids (oral or inhaled) according to the intensity of bronchial eosinophilic inflammation in patients with COPD was significantly superior in preventing exacerbations and improving health-related quality of life compared with the prescription of ICS according to current guidelines [38, 39].

Already in 2007 the Canadian guidelines specified that: “if the asthma component (in COPD) is prominent, earlier introduction of ICS may be justified” [40]. Later, in 2010, the Japanese guidelines of COPD dedicated a chapter to “Treatment of COPD complicated by asthma” [41] and indicate that ICS combined with long-acting beta-2 agonists (LABA) would be the first choice treatment irrespective of the level of airflow obstruction. More recently, the Spanish guidelines of COPD, the Czech Republic guidelines and the Finnish guidelines address the indication of ICS in the patients with ACOS in all stages of severity [13, 14].

New treatments targeting a reduction in eosinophilic concentrations are being developed. Among them, the anti-IL5 benralizumab has not proven to reduce exacerbations in COPD patients with peripheral eosinophilia, but patients with the highest eosinophilic count showed improvements in FEV1 and a reduction in the exacerbations rate, which support further investigation [42].

Conclusion
Patients with ACOS show 3 characteristic features that help us to identify them: enhanced bronchial and systemic eosinophilic inflammation, increased reversibility of airflow and increased response to ICS compared with patients with COPD alone. Whether one believes in the existence of ACOS or just in the coexistence of these two different diseases in the same individual, it is clear that patients with ACOS are different from those with asthma and COPD. Although these patients share features with both asthma and COPD, they have some different clinical characteristics and prognosis and what it more important, a better response to ICS.

Abbreviations
ACOS: Asthma-COPD overlap disease; COPD: Chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; BHR: bronchial hyperresponsiveness; LABA: long acting β2 agonist; DLCO: carbon monoxide diffusing capacity; CO: carbon monoxide; SP-A: surfactant protein A; iRAGE: soluble receptor for advanced glycation end products; MPO: mieloperoxidase; NGAL: neutrophil gelatinase associated lipocalin.

Competing interests
Marc Miravitlles has received speaker fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, Esteve, GlaxoSmithKline, Menarini, Grifols, Novartis, and Novartis, and consulting fees from Almirall, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Gebro Pharma, CLS Behring, MedImmune, Novartis, Grifols and Novartis. Miriam Barrecheguren and Cristina Esquinas have no conflict of interest to disclose.

Authors' contributions
All authors wrote, read and approved the final manuscript.

Received: 25 May 2015 Accepted: 24 August 2015
Published online: 22 October 2015

References


